Cargando…
Drug screening model meets cancer organoid technology
Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived x...
Autores principales: | Liu, Chen, Qin, Tianyu, Huang, Yuhan, Li, Yuan, Chen, Gang, Sun, Chaoyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451679/ https://www.ncbi.nlm.nih.gov/pubmed/32822897 http://dx.doi.org/10.1016/j.tranon.2020.100840 |
Ejemplares similares
-
Application of Cancer Organoid Model for Drug Screening and Personalized Therapy
por: Kondo, Jumpei, et al.
Publicado: (2019) -
Patient‐derived organoids for personalized gallbladder cancer modelling and drug screening
por: Yuan, Bo, et al.
Publicado: (2022) -
Six Gynecological Cancer Patients Infected With SARS-CoV-2 After Surgery or Radio-/Chemo-Therapy Treatment: Case Series
por: Liu, Chen, et al.
Publicado: (2020) -
Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
por: Xu, Hanxiao, et al.
Publicado: (2018) -
Organoid of ovarian cancer: genomic analysis and drug screening
por: Liu, H.-D., et al.
Publicado: (2020)